Prelude Therapeutics Incorporated
PRLDNASDAQHealthcare● Active
$3.84
+$0.03(+0.79%)
Market Cap$218621864
P/E Ratio—
52W High$5.54
52W Low$0.75
Prelude Therapeutics Incorporated (PRLD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRLD · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.13
Est. -$0.27 · +51.9%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS🔥 11-Quarter EPS Beat Streak
PRLD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.23 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.27 | -$0.13 | +51.9% | $0.00B | $0.00B | +0.0% |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$0.33 | -$0.20 | +39.4% | $0.01B | $0.02B | -72.7% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.35 | -$0.26 | +25.7% | $0.01B | $0.02B | -68.3% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.45 | -$0.41 | +8.9% | — | — | — |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.47 | -$0.42 | +10.6% | — | — | — |
| ▲ Q1 FY2025 | Mar 10, 2025 | -$0.49 | -$0.38 | +22.4% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.48 | -$0.43 | +10.4% | $0.00B | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.13
EPS Est.
-$0.27
EPS Surpr.
+51.9%
Revenue
$0.00B
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.33
EPS Surpr.
+39.4%
Revenue
$0.01B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.35
EPS Surpr.
+25.7%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.41
EPS Est.
-$0.45
EPS Surpr.
+8.9%
Revenue
—
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.42
EPS Est.
-$0.47
EPS Surpr.
+10.6%
Revenue
—
Q1 FY2025
Mar 10, 2025Beat
EPS Actual
-$0.38
EPS Est.
-$0.49
EPS Surpr.
+22.4%
Revenue
$0.00B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.43
EPS Est.
-$0.48
EPS Surpr.
+10.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2028 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Q2 FY2028 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q1 FY2028 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Q4 FY2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +51.9% | $4.80 | $4.64 | -3.33% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +39.4% | $3.09 | $3.60 | +16.50% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +25.7% | $1.35 | $1.47 | +8.89% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +8.9% | $0.91 | $0.95 | +4.19% |
| ▲ Q2 FY2025 | May 6, 2025 | +10.6% | $0.82 | $0.80 | -3.12% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +22.4% | $0.74 | $0.67 | -8.97% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +10.4% | $1.29 | $1.32 | +2.33% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +0.0% | $5.10 | $4.75 | -6.86% |
Q2 FY2026-3.33%
Report Date
May 12, 2026
EPS Beat/Miss
+51.9%
Price Before
$4.80
Price After
$4.64
Q1 FY2026+16.50%
Report Date
Mar 10, 2026
EPS Beat/Miss
+39.4%
Price Before
$3.09
Price After
$3.60
Q4 FY2025+8.89%
Report Date
Nov 12, 2025
EPS Beat/Miss
+25.7%
Price Before
$1.35
Price After
$1.47
Q3 FY2025+4.19%
Report Date
Aug 14, 2025
EPS Beat/Miss
+8.9%
Price Before
$0.91
Price After
$0.95
Q2 FY2025-3.12%
Report Date
May 6, 2025
EPS Beat/Miss
+10.6%
Price Before
$0.82
Price After
$0.80
Q1 FY2025-8.97%
Report Date
Mar 10, 2025
EPS Beat/Miss
+22.4%
Price Before
$0.74
Price After
$0.67
Q4 FY2024+2.33%
Report Date
Nov 6, 2024
EPS Beat/Miss
+10.4%
Price Before
$1.29
Price After
$1.32
Q3 FY2024-6.86%
Report Date
Aug 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$5.10
Price After
$4.75
Avg Beat Reaction+1.20%
Beat Rate8 / 8 quarters
Largest Move+16.50% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRLD ends December
Prelude Therapeutics Incorporated (PRLD) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.13 — beating the analyst consensus of $-0.27 by +51.9%. PRLD has beaten EPS estimates for 11 consecutive quarters. The next PRLD earnings date is expected around September 1, 2026.
Each quarter, investors track PRLD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRLD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRLD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRLD earnings · 5 questionsPrelude Therapeutics Incorporated's next earnings report is expected around September 1, 2026. PRLD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRLD historically reports after market close (AMC).
PRLD earnings datewhen is PRLD earningsPRLD next earnings datewhen does PRLD report earningsPRLD earnings calendar
▸ Source: FMP · Prelude Therapeutics Incorporated SEC filings · US GAAP · Prelude Therapeutics Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026